NCT01115907已完成3 期
Clinical Investigation of the Freedom SOLO Stentless Heart Valve in North America
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 251
- 试验地点
- 27
- 主要终点
- Safety will be determined by incidence rate of adverse events
研究概览
简要总结
The purpose of this clinical investigation is to demonstrate the safety and effectiveness of the Freedom SOLO heart valve.
详细描述
The SOLO clinical investigation is a prospective, non-randomized, multicenter trial of the SOLO Freedom heart valve implanted in patients requiring aortic valve replacement.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subject is male or female 18 years old or older.
- •The subject or subject's legal representative is willing to sign the informed consent.
- •The subject which preoperative evaluation indicated the need for native or prosthetic aortic valve replacement.
- •Any subject amenable to aortic valve replacement with biological prosthesis should be enrolled in the study, even in conjunction with valve repair, coronary artery bypass grafting and other procedures.
- •The subject is located in a geographic location that will enable the subject to return to the study site for all follow-up examinations (i.e. geographically stable).
- •Subject will be available to the investigator(s) for postoperative follow-up beyond one year.
排除标准
- •The subject has preexisting valve prosthesis in the mitral, pulmonary or tricuspid position.
- •The subject requires a double or multiple valve replacement (a valve repair is not considered an exclusion criterion).
- •The subject has a previously implanted SOLO valve, within the clinical study, that requires replacement.
- •The subject has active endocarditis or myocarditis.
- •The subject is or will be participating in a concomitant research study of an investigational product.
- •The subject is a minor, drug abuser, alcohol abuser, prison inmate, institutionalized, or is unable to give informed consent.
- •The subject has a major or progressive non-cardiac disease that, in the investigator's experience, results in a life expectancy of less than 1 year, or the implant of the device produces an unacceptable increased risk to the subject.
- •The subject is pregnant, planning to become pregnant or lactating.
- •The subject has a congenital bicuspid aortic valve.
- •The subject is known to be noncompliant or is unlikely to complete the study.
- •The subject is undergoing renal dialysis for chronic renal failure or has been diagnosed with hyperparathyroidism.
- •The subject has had an acute preoperative neurological deficit, myocardial infarction, or cardiac event that has not returned to baseline or stabilized ≥30 days prior to the planned valve implant surgery.
- •The subject has extensive calcification of the aortic root where removal of the calcified tissue cannot be achieved.
- •The subject has a significantly dilated aortic root that is not surgically corrected.
- •The subject requires replacement of the aortic root / full root procedure.
结局指标
主要结局
Safety will be determined by incidence rate of adverse events
时间窗: 1 year
The complication and survival rates for the SOLO valve are comparable to appropriate historical controls manifested as objective performance criteria (OPCs) and to that reported in the literature for other stentless bioprostheses and stented pericardial valves.
次要结局
- Efficacy will be determined by hemodynamics(1 year)
- Effectiveness will be determined by NYHA Classification comparisons(1 year)
研究者
研究点 (27)
Loading locations...
相似试验
已完成
不适用
Clinical Investigation of the Freedom SOLO Stentless Heart ValveHeart Valve DiseasesNCT00876525Corcym S.r.l702
已完成
早期 1 期
A Clinical Study Evaluating the Safety and Efficacy of CS-101 in Treating Subjects With β-thalassemiaBeta-ThalassemiaNCT06024876CorrectSequence Therapeutics Co., Ltd5
Enrolling By Invitation
1 期
CS-101 in Patients With β-thalassemiaBeta-ThalassemiaNCT06328764CorrectSequence Therapeutics Co., Ltd10
已完成
1 期
Safety Study of Antria Cell Preparation Process to Enhance Facial Fat Grafting With Adipose Derived Stem CellsLipoatrophyAgingWrinklesNCT01828723Antria6
终止
2 期
Efficacy and Safety of DLBS1425 in Subjects With Advanced/Metastatic Breast CancerBreast CancerNCT01006785Dexa Medica Group15